10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: Study protocol for a randomised controlled trial

Victor M. Oguoma, Nicole Wilson, Kim Mulholland, Mathuram Santosham, Paul Torzillo, Peter McIntyre, Heidi Smith-Vaughan, Anne Balloch, Mark Chatfield, Deborah Lehmann, Michael J. Binks, Anne Chang, Jonathan Carapetis, Vicki Krause, Ross Andrews, Tom Snelling, Paul Licciardi, Peter Morris, Amanda Jane Leach

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)
57 Downloads (Pure)

Fingerprint

Dive into the research topics of '10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: Study protocol for a randomised controlled trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science